A look at ligand binding thermodynamics in drug discovery

References

• Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5:730–739.
   PubMed Web of Science ®Google Scholar
• Copeland RA. The drug–target residence time model: a 10-year retrospective. Nat Rev Drug Discov. 2016;15:87–95.
   PubMed Web of Science ®Google Scholar
• Holdgate GA, Gill AL. Kinetic efficiency: the missing metric for enhancing compound quality? Drug Discov Today. 2011;16:910–913.
   PubMed Web of Science ®Google Scholar
• Ladbury JE, Chowdhry BZ. Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions. Chem Biol. 1996;3:791–801.
   PubMedGoogle Scholar
• Jelesarov I, Bosshard HR. Isothermal titration calorimetry and differential scanning calorimetry as complementary tools to investigate the energetics of biomolecular recognition. J Mol Recognit. 1999;12:3–18.
   PubMed Web of Science ®Google Scholar
• Perozzo R, Folkers G, Scapozza L. Thermodynamics of protein-ligand interactions: history, presence, and future aspects. J Recept Signal Transduct Res. 2004;24:1–52.
   PubMed Web of Science ®Google Scholar
• Holdgate GA, Ward WH. Measurements of binding thermodynamics in drug discovery. Drug Discov Today. 2005;10:1543–1550.
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Todd MJ, Freire E. HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. Biochemistry. 2000;39:2201–2207.
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Kiso Y, Freire E. The binding energetics of first and second generation HIV-1 protease inhibitors: implications for drug design. Arch Biochem Biophys. 2001;390:169–175.
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Luque I, Freire E. The application of thermodynamic methods in drug design. Thermochim Acta. 2001;380:217–227.
   Web of Science ®Google Scholar
• Ohtaka H, Muzammil S, Schon A, et al. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. Int J Biochem Cell Biol. 2004;36:1787–1799.
   PubMed Web of Science ®Google Scholar
• Freire E. A thermodynamic guide to affinity optimization of drug candidates. In: Waksman G, ed. Proteomics and protein-protein interactions: biology, chemistry, bioinformatics, and drug design. New York: Springer; 2005. p. 291–307.
   Google Scholar
• Holdgate GA. Thermodynamics of binding interactions in the rational drug design process. Expert Opin Drug Discov. 2007;2:1103–1114.
   PubMed Web of Science ®Google Scholar
• Ladbury JE, Klebe G, Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov. 2010;9:23–27 .
   PubMed Web of Science ®Google Scholar
• Ferenczy GG, Keseru GM. Thermodynamics guided lead discovery and optimization. Drug Discov Today. 2010;15:919–932.
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Muzammil S, Ohtaka H, et al. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr Drug Targets Infect Disord. 2003;3:311–328.
   PubMedGoogle Scholar
• Nezami A, Kimura T, Hidaka K, et al. High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry. 2003;42:8459–8464.
   PubMed Web of Science ®Google Scholar
• Carbonell T, Freire E. Biochemistry. Binding thermodynamics of statins to HMG-CoA reductase. Biochemistry. 2005;44:11741–11748.
   PubMed Web of Science ®Google Scholar
• Klebe G. Applying thermodynamic profiling in lead finding and optimization. Nat Rev Drug Discov. 2015;14:95–110.
   PubMed Web of Science ®Google Scholar
• Olsson TS, Ladbury JE, Pitt WR, et al. Extent of enthalpy-entropy compensation in protein-ligand interactions. Protein Sci. 2011;20:1607–1618.
   PubMed Web of Science ®Google Scholar
• Chodera JD, Mobley DL. Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. Annu Rev Biophys. 2013;42:121–142.
   PubMed Web of Science ®Google Scholar
• Geschwindner S, Ulander J, Johansson P. Ligand binding thermodynamics in drug discovery: still a hot tip? J Med Chem. 2015;58:6321–6335.
   PubMed Web of Science ®Google Scholar
• Chaires JB. Calorimetry and thermodynamics in drug design. Annu Rev Biophys. 2008;37:135–151.
   PubMed Web of Science ®Google Scholar
• Garbett NC, Chaires JB. Thermodynamic studies for drug design and screening. Expert Opin Drug Discov. 2012;7:299–314.
   PubMed Web of Science ®Google Scholar
• Renaud JP, Chung CW, Danielson UH, et al. Biophysics in drug discovery: impact, challenges and opportunities. Nat Rev Drug Discov. 2016;15:679–698.
   PubMed Web of Science ®Google Scholar
• Eftink M, Biltonen R. Thermodynamics of interacting biological systems. In: Beezer AE, ed. Biological Calorimetry. London: Academic Press; 1980. p. 343–412.
   Google Scholar
• Wyman J, Gill SJ. Binding and linkage: functional chemistry of biological macro-molecules. Mill Valley: University Science Books; 1990.
   Google Scholar
• Vega S, Abian O, Velazquez-Campoy A. On the link between conformational changes, ligand binding and heat capacity. BBA - Gen Subjects. 2016;1860:868–878.
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Goñi G, Peregrina JR, et al. Exact analysis of heterotropic interactions in proteins: characterization of cooperative ligand binding by isothermal titration calorimetry. Biophys J. 2006;91:1887–1904.
   PubMed Web of Science ®Google Scholar
• Vega S, Abian O, Velazquez-Campoy A. A unified framework based on the binding polynomial for characterizing biological systems by isothermal titration calorimetry. Methods. 2015;76:99–115.
   PubMed Web of Science ®Google Scholar
• Parsegian VA, Rand RP, Rau DC. Macromolecules and water: probing with osmotic stress. Methods Enzymol. 1995;259:43–94.
   PubMed Web of Science ®Google Scholar
• Hinz HJ. Thermodynamics of protein-ligand interactions: calorimetric approaches. Annu Rev Biophys Bioeng. 1983;12:285–317.
   PubMedGoogle Scholar
• Hinz HJ, Shiao DDF, Sturtevant JM. Calorimetric investigation of inhibitor binding to rabbit muscle aldolase. Biochemistry. 2971;10:1347–1352.
   Google Scholar
• Baker BM, Murphy KP. Evaluation of linked protonation effects in protein binding reactions using isothermal titration calorimetry. Biophys J. 1996;71:2049–2055.
   PubMed Web of Science ®Google Scholar
• Xie D, Gulnik S, Collins L, et al. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues. Biochemistry. 1997;36:16166–16172.
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Luque I, Todd MJ, et al. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci. 2000;9:1801–1809.
   PubMed Web of Science ®Google Scholar
• Linkuviene V, Matuliene J, Juozapaitiene V, et al. Intrinsic thermodynamics of inhibitor binding to human carbonic anhydrase IX. BBA - Gen Subjects. 2016;1860:708–718.
   PubMed Web of Science ®Google Scholar
• Gomez J, Hilser VJ, Xie D, et al. The heat capacity of proteins. Proteins. 1995;22:404–412.
   PubMed Web of Science ®Google Scholar
• Prabhu NV, Sharp KA. Heat capacity of proteins. Annu Rev Phys Chem. 2005;56:521–548.
   PubMed Web of Science ®Google Scholar
• Syme NR, Dennis C, Philips SEV, et al. Origin of heat capacity changes in a “nonclassical” hydrophobic interaction. ChemBioChem. 2007;8:1509–1511.
   PubMed Web of Science ®Google Scholar
• Gallagher K, Sharp K. Electrostatic contributions to heat capacity changes of DNA-ligand binding. Biophys J. 1998;75:769–776.
   PubMed Web of Science ®Google Scholar
• Cabani S, Gianni P, Mollica V, et al. Group contributions to the thermodynamic properties of non-ionic organic solutes in dilute aqueous solution. J Solution Chem. 1981;10:563–595.
   Web of Science ®Google Scholar
• Wand AJ. The dark energy of proteins comes to light: conformational entropy and its role in protein function revealed by NMR relaxation. Curr Opin Struct Biol. 2013;23:75–81.
   PubMed Web of Science ®Google Scholar
• Martin SF, Clements JH. Correlating structure and energetics in protein-ligand interactions: paradigms and paradoxes. Annu Rev Biochem. 2013;82:267–293.
   PubMed Web of Science ®Google Scholar
• Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 2009;8(3):203–212.
   PubMed Web of Science ®Google Scholar
• Freire E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today. 2008;13:869–874.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Sekiguchi M, Kawasaki M, et al. Thermodynamic evaluation of the binding of bisphosphonates to human farnesyl pyrophosphate synthase. Chem Pharm Bull (Tokyo). 2014;62:77–83.
   PubMed Web of Science ®Google Scholar
• Ohtaka H, Freire E. Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol. 2005;88:193–208.
   PubMed Web of Science ®Google Scholar
• Ruben AJ, Kiso Y, Freire E. Overcoming roadblocks in lead optimization: A thermodynamic perspective. Chem Biol Drug Des. 2006;67:2–4.
   PubMed Web of Science ®Google Scholar
• Freeman-Cook KD, Hoffman RL, Johnson TW. Lipophilic efficiency: the most important efficiency metric in medicinal. Future Med Chem. 2013;5:113–115.
   PubMed Web of Science ®Google Scholar
• Hughes JD, Blagg J, Price DA, et al. Physiocochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett. 2008;18:4872–4875.
   PubMed Web of Science ®Google Scholar
• Waring MJ. Lipophilicity in drug discovery. Expert Opin Drug Discov. 2010;5:235–248.
   PubMed Web of Science ®Google Scholar
• Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov. 2012;7:863–875.
   PubMed Web of Science ®Google Scholar
• Tarcsay A, Keseru GM. Contributions of molecular properties to drug promiscuity. J Med Chem. 2013;56:1789–1795.
   PubMed Web of Science ®Google Scholar
• Gleeson MP, Hersey A, Montanari D, et al. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov. 2011;10:197–208.
   PubMed Web of Science ®Google Scholar
• Tarcsay A, Nyiri K, Keseru GM. Impact of lipophilic efficiency on compound quality. J Med Chem. 2012;55:1252–1260.
   PubMed Web of Science ®Google Scholar
• Shultz MD. The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations. Bioorg Med Chem Lett. 2013;23:5992–6000.
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Keseru GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13:105–121.
   PubMed Web of Science ®Google Scholar
• Freire E. The binding thermodynamics of drug candidates. In: Keseru GM, Swinney DC, ed. Thermodynamics and kinetics of drug binding. Weinheim:Wiley-VCH Verlag GmbH; 2015. p. 3–13.
   Google Scholar
• Tarcsay A, Keseru GM. Is there a link between selectivity and binding thermodynamics profiles? Drug Discov Today. 2015;20:86–94.
   PubMed Web of Science ®Google Scholar
• Iakovleva I, Brannstroom K, Nilsson L, et al. Enthalpic forces correlate with the selectivity of transthyretin-stabilizing ligands in human plasma. J Med Chem. 2015;58:6507–6515.
   PubMed Web of Science ®Google Scholar
• Bertini I, Calderone V, Fragai M, et al. Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases. J Am Chem Soc. 2007;129:2466–2475.
   PubMed Web of Science ®Google Scholar
• Merighi S, Simioni C, Gessi S, et al. Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors. Biochem Pharmacol. 2009;79:471–477.
   PubMed Web of Science ®Google Scholar
• Lafont V, Armstrong AA, Ohtaka H, et al. Compensating enthalpic and entropic changes hinder binding affinity optimization. Chem Biol Drug Des. 2007;69:413–422.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Freire E. Finding a better path to drug selectivity. Drug Discov Today. 2011;16:985–990.
   PubMed Web of Science ®Google Scholar
• Velazquez-Campoy A, Freire E. Incorporating target heterogeneity in drug design. J Cell Biochem. 2001;84(S37):82–88.
   Web of Science ®Google Scholar
• Vega S, Kang LW, Velazquez-Campoy A, et al. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease. Proteins. 2004;55:594–602.
   PubMed Web of Science ®Google Scholar
• Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420:678–682.
   PubMed Web of Science ®Google Scholar
• Courter JR, Madani N, Sodroski J, et al. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Acc Chem Res. 2014;47:1228–1237.
   PubMed Web of Science ®Google Scholar
• Edink E, Rucktooa P, Retra K, et al. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. J Am Chem Soc. 2011;133:5363–5371.
   PubMed Web of Science ®Google Scholar
• Schon A, Madani N, Klein JC, et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry. 2006;45:10973–10980.
   PubMed Web of Science ®Google Scholar
• Schon A, Madani N, Smith III AB, et al. Some binding-related drug properties are dependent on thermodynamic signature. Chem Biol Drug Des. 2011;77:161–165.
   PubMed Web of Science ®Google Scholar
• Bissantz C, Kuhn B, Stahl M. A medicinal chemist’s guide to molecular interactions. J Med Chem. 2010;53:5061–5084.
   PubMed Web of Science ®Google Scholar
• Talhout R, Villa A, Mark AE, et al. Understanding binding affinity: a combined isothermal titration calorimetry/molecular dynamics study of the binding of a series of hydrophobically modified benzamidinium chloride inhibitors to trypsin. J Am Chem Soc. 2003;125:10570–10579.
   PubMed Web of Science ®Google Scholar
• Fenley AT, Muddana HS, Gilson MK. Entropy-enthalpy transduction caused by conformational shifts can obscure the forces driving protein-ligand binding. Proc Natl Acad Sci USA. 2012;109:20006–20011.
   PubMed Web of Science ®Google Scholar
• Breiten B, Lockett MR, Sherman W, et al. Water networks contribute to enthalpy/entropy compensation in protein-ligand binding. J Am Chem Soc. 2013;135:15579–15584.
   PubMed Web of Science ®Google Scholar
• Zafra-Ruano A, Luque I. Interfacial water molecules in SH3 interactions: getting the full picture on polyproline recognition by protein-protein interaction domains. FEBS Lett. 2012;586:2619–2630.
   PubMed Web of Science ®Google Scholar
• Steuber H, Heine A, Klebe G. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution. J Mol Biol. 2007;368:618–638.
   PubMed Web of Science ®Google Scholar
• Eftink MR, Anusiem AC, Biltonen RL. Enthalpy-entropy compensation and heat capacity changes for protein-ligand interactions: general thermodynamic models and data for the binding of nucleotides to ribonuclease A. Biochemistry. 1983;22:3884–3896.
   PubMed Web of Science ®Google Scholar
• Tellinghuisen J, Chodera JD. Systematic errors in isothermal titration calorimetry: concentrations and baselines. Anal Biochem. 2011;414:297–299.
   PubMed Web of Science ®Google Scholar
• Tellinghuisen J. Isothermal titration calorimetry at very low c. Anal Biochem. 2008;373:395–397.
   PubMed Web of Science ®Google Scholar
• Williams R, Holyoak T, McDonald G, et al. Differentiating a ligand’s chemical requirements for allosteric interactions from those for protein binding. Phenylalanine inhibition of pyruvate kinase. Biochemistry. 2006;45:5421–5429.
   PubMed Web of Science ®Google Scholar
• Ruiz-Ramos A, Velazquez-Campoy A, Grande-Garcia A, et al. Structure and functional characterization of human aspartate transcarbamoylase, the target of the anti-tumoral drug PALA. Structure. 2016;24:1081–1094.
   PubMed Web of Science ®Google Scholar
• Liu Y, Schon A, Freire E. Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis. Chem Biol Drug Des. 2013;81:72–78.
   PubMed Web of Science ®Google Scholar
• Jobichen C, Fernandis AZ, Velazquez-Campoy A, et al. Identification and characterization of the lipid-binding property of GrlR, a locus of enterocyte effacement regulator. Biochem J. 2009;420:191–199.
   PubMed Web of Science ®Google Scholar
• Ladbury JE, Williams MA. The extended interface: measuring non-local effects in biomolecular interactions. Curr Opin Struct Biol. 2004;14:562–569.
   PubMed Web of Science ®Google Scholar
• Schon A, Freire E. Enthalpy screen of drug candidates. Anal Biochem. 2016;513:1–6.
   PubMed Web of Science ®Google Scholar
• Freire E. A thermodynamic approach to the affinity optimization of drug candidates. Chem Biol Drug Des. 2009;74:468–472.
   PubMed Web of Science ®Google Scholar
• Ferenczy GG, Keseru GM. Enthalpic efficiency of ligand binding. J Chem Inf Model. 2010;50:1536–1541.
   PubMed Web of Science ®Google Scholar
• Markova N, Hallen D. The development of a continuous isothermal titration calorimetric method for equilibrium studies. Anal Biochem. 2004;331:77–88.
   PubMed Web of Science ®Google Scholar